112 related articles for article (PubMed ID: 37797805)
1. Synthesis and preliminary biological evaluation of a novel
Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M
Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805
[TBL] [Abstract][Full Text] [Related]
2. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Imaging of Tumor PD-L1 Expression Using [
Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
[TBL] [Abstract][Full Text] [Related]
5. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J
Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488
[TBL] [Abstract][Full Text] [Related]
6. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
7. Novel small
Liang Z; Hu X; Hu H; Wang P; Cai J
Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
[TBL] [Abstract][Full Text] [Related]
8. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development and characterisation of
Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
[TBL] [Abstract][Full Text] [Related]
10. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
12. A novel
Ge S; Zhang B; Li J; Shi J; Jia T; Wang Y; Chen Z; Sang S; Deng S
Bioorg Chem; 2023 Nov; 140():106785. PubMed ID: 37639759
[TBL] [Abstract][Full Text] [Related]
13. Implication of
Gao Y; Luo Q; Sun Z; Gao H; Yu Y; Sun Y; Ma X; Han C; Shi J; Wang F
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36858461
[TBL] [Abstract][Full Text] [Related]
14.
Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
[TBL] [Abstract][Full Text] [Related]
15. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
16. Inter- and intraobserver agreement of the quantitative assessment of [
Hughes DJ; Chand G; Goh V; Cook GJR
EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
[TBL] [Abstract][Full Text] [Related]
17. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
19. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
[TBL] [Abstract][Full Text] [Related]
20. Construction of Anti-hPD-L1 HCAb Nb6 and
Huang HF; Zhu H; Li GH; Xie Q; Yang XT; Xu XX; Tian XB; Wan YK; Yang Z
Bioconjug Chem; 2019 Oct; 30(10):2614-2623. PubMed ID: 31535847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]